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Characterization of Liver
Lesions with Mangafodipir
Trisodium–enhanced MR
Imaging: Multicenter Study
Comparing MR and
Dual-Phase Spiral CT1
PURPOSE: To evaluate whether mangafodipir trisodium (Mn-DPDP)–enhanced
magnetic resonance (MR) imaging surpasses dual-phase spiral computed tomogra-
phy (CT) in differentiating focal liver lesions.
MATERIALS AND METHODS: One hundred forty-five patients who had or were
suspected of having focal liver lesions were included in a multicenter study and
underwent dual-phase spiral CT and enhanced MR imaging. Image interpretations
performed by independent experienced radiologists were compared with the final
diagnosis that was based on all available clinical information (including histopatho-
logic findings in 77 patients) and that was determined with consensus. Differences
in classifications by using either enhanced MR imaging or dual-phase spiral CT were
analyzed with the McNemar test, and receiver operating characteristic (ROC) curves
were used to compare the diagnostic performance of enhanced MR imaging and
dual-phase spiral CT.
RESULTS: Lesion classification was correct in 108 (74%) patients with enhanced MR
imaging and in 83 (57%) with dual-phase spiral CT (P  .001). Lesions were
correctly classified as either malignant or benign in 123 (85%) patients with en-
hanced MR imaging and in 98 (68%) with dual-phase spiral CT (P  .001).
Classification of lesions as either hepatocellular or nonhepatocellular was correct in
130 (90%) patients with enhanced MR imaging and in 93 (64%) with dual-phase
spiral CT (P  .001). These differences remained when analyses were restricted to
histopathologically confirmed diagnoses. Comparison of the ROC curves illustrated
that enhanced MR imaging performance surpassed that of dual-phase spiral CT.
CONCLUSION: Mn-DPDP–enhanced MR imaging is superior to dual-phase spiral
CT in classification of focal liver lesions.
© RSNA, 2002
In planning the therapeutic approach for patients who have or are suspected of having
liver lesions, imaging is one of the major sources of information (1). Although ultrasonog-
raphy (US) will depict most of the focal liver lesions, characterization of the nature of such
lesions often depends on an additional imaging evaluation, sometimes followed by a
histopathologic examination. The two principal modalities for the additional imaging
evaluation of the liver, computed tomography (CT) and magnetic resonance (MR) imag-
ing, have undergone marked technical advances over the past few years (1,2). As to focal
liver lesion detection, it is now generally accepted that contrast material–enhanced CT
scanning (dynamic or multiphasic) is roughly comparable to unenhanced MR imaging
with optimized pulse sequences for liver imaging (3,4) and inferior to contrast-enhanced
MR imaging with gadolinium chelates (5–7), iron oxide compounds (8–10), and manganese
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chelates (11–14). Lesion characterization,
on the other hand, has not been as in-
tensively compared as lesion detection.
Results of studies comparing lesion char-
acteristics by using these two modalities
are inconclusive, mainly owing to diffi-
culty to maintain the comparability of
these two modalities in the study design.
For convincing comparisons, both mo-
dalities need to represent state-of-the-art
techniques, which implies that liver-spe-
cific rather than nonspecific contrast
agents should be used when available.
Mangafodipir trisodium (Mn-DPDP) has
a special affinity for hepatocytes and thus
represents such a liver-specific MR con-
trast agent (12,13,15). Following intra-
venous administration, the Mn-DPDP
chelate dissociates slowly, and the man-
ganese is taken up by the hepatocytes.
This leads to an increase in signal intensity
of normal liver parenchyma on the T1-
weighted image caused by T1 shortening
and, thereby, to an increase in contrast be-
tween normal and abnormal tissue (13,16).
Because there are no liver-specific CT con-
trast agents available, it would seem that
Mn-DPDP–enhanced MR imaging might
allow a more specific diagnosis to be estab-
lished for focal liver lesions than dual-
phase spiral CT.
The purpose of this prospective multi-
center clinical phase 3 study was to com-
pare the ability to differentiate focal liver
lesions by using Mn-DPDP–enhanced
MR imaging and contrast-enhanced dual-
phase spiral CT, both of which represent
state-of-the-art techniques (11,13,16–23).
MATERIALS AND METHODS
Study Population
Eligible patients were to be conscious,
cooperative, and scheduled to be radio-
logically examined because they had or
were suspected of having liver lesions (as
seen at a US, CT, or MR examination
within 4 weeks prior to inclusion) so that
different types of benign and malignant
focal liver lesions could be distinguished.
Medical history, possible risk factors, and
concomitant medication were noted
prior to Mn-DPDP–enhanced MR imag-
ing or dual-phase spiral CT.
Patients were excluded if they were less
than 18 years old; they were pregnant or
breast-feeding; they had a clinically un-
stable condition or an active, serious,
and/or life-threatening disease (eg, life
expectancy less than a month); they had
severe unrelieved obstructive hepatobiliary
disease (serum bilirubin, 47.5 mol/L
[2.5 mg/100 mL]); they had severe renal
impairment (serum creatinine, 133
mol/L [1.5 mg/100 mL]); they had or
were suspected of having pheochromocy-
toma; they had contraindications for MR
imaging or CT; they had received or were
scheduled to receive another contrast me-
dium (for MR imaging, radiography, or US)
within 12 hours prior to or 24 hours after
the proposed dual-phase spiral CT and Mn-
DPDP–enhanced MR examinations; they
were previously included in this trial or
they were simultaneously or had previ-
ously participated in or planned to partic-
ipate in another clinical trial with intake of
an investigational drug within the 7 days
prior to or after participation in this trial.
From December 1996 to September
1998, 152 consecutive patients (62 [41%]
women, 90 [59%] men; mean age, 59
years; age range, 28–83 years) were en-
rolled in the present six-center (Nether-
lands, Belgium, Spain, Germany [includ-
ing two centers] and England) open-label
study. Written informed consent was ob-
tained from each patient after the nature
of the procedures had been fully ex-
plained. Approval from the ethics com-
mittee of each center was also obtained.
After dual-phase spiral CT, Mn-DPDP–
enhanced MR imaging was performed
minimally 24 hours later and maximally
a week later.
Imaging Methods
In all participants, transverse dual-phase
spiral CT scans and Mn-DPDP–enhanced
MR images were obtained and included the
whole liver during one breath hold (after
maximal inspiration) in cranial caudal di-
rection.
For dual-phase spiral CT (Somatom
Plus 4; Siemens, Erlangen, Germany), af-
ter an initial scout scan, images (120 kV;
210 mA; section thickness, 5 mm; table
speed, 10 mm/sec; rotation, 1/sec; acqui-
sition time, approximately 20 seconds;
field of view, 350 mm) were acquired be-
fore administration of contrast material.
Afterward a total of 150 mL (adminis-
tered at 4 mL/sec for 37.5 seconds) of
iohexol (Omnipaque 300; Nycomed Im-
aging, Oslo, Norway) was administered
intravenously with a programmed CT in-
jector (EnVision; Medrad, Indianola, Pa),
and scans were obtained 21 and 66 sec-
onds after the start of the injection dur-
ing the arterial and portal phases, respec-
tively.
For Mn-DPDP–enhanced MR imaging,
a 1.5-T unit (Magnetom Vision; Siemens,
Erlangen, Germany) was used. After initial
scout images, precontrast images with a
section thickness of 5 mm (no gap) and
T1-weighted gradient-echo (repetition
time msec/echo time msec, 170/4.4; flip
angle, 80°; field of view, 350 mm; number
of sections, 21) and T2-weighted turbo
spin-echo MR images (3,200/138; flip an-
gle, 180°; field of view, 350 mm; number of
sections, 10) were obtained with a circular-
phased body phased-array coil (total imag-
ing time, approximately 1 hour). Hereafter,
0.005 mmol (0.5 mL) per kilogram of body
weight of Mn-DPDP (Teslascan; Nycomed
Imaging, Oslo, Norway) was administered
intravenously (slow injection at 2.5 mL/
min). Mn-DPDP–enhanced MR imaging
was initiated 15–30 minutes after adminis-
tration of the contrast agent with the same
protocol and sequences as described previ-
ously. Adverse events were recorded for
both imaging modalities.
Image Interpretation
All Mn-DPDP–enhanced MR images
and dual-phase spiral CT scans were cen-
trally collected, and hard copies were in-
terpreted off site by experienced radiolo-
gists who were blinded to any clinical,
laboratory, or other imaging information
and who were chosen from nonpartici-
pating medical institutions. Independent
from each other, an MR radiologist (J.F.C.)
evaluated the Mn-DPDP–enhanced MR
images, whereas a CT radiologist evaluated
the dual-phase spiral CT scans. In case their
diagnoses were different, the images were
reinterpreted by two other radiologists
without knowledge of the prior interpreta-
tion. In case of disagreement between the
first interpretation (determined by the MR
and CT radiologists) and the second inter-
pretation (determined by two other radiol-
ogists) of the same image, a consensus
panel, including the two original radiolo-
gists (CT and MR radiologists) plus an in-
dependent third, decided on the final in-
terpretation.
For those cases in which the CT and
MR radiologists agreed, the final interpre-
tation was the first interpretation that
they determined. Each reader was re-
quired to answer several questions for
each patient regarding the lesion (absent
vs present), the nature of the lesion (ma-
lignant vs benign), the type of the lesion
(hepatocellular vs nonhepatocellular),
and the most likely etiologic diagnosis.
Lesions were characterized according to
their characteristic imaging appearance
on the Mn-DPDP–enhanced MR image
or dual-phase spiral CT scan. On Mn-
DPDP–enhanced MR images, lesions
were considered of hepatocytic origin if
there was enhancement on T1-weighted
Mn-DPDP–enhanced MR images. Further
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classification was possible with examina-
tion of the enhancement pattern of the
lesion. For the most common focal liver
lesions, the discriminating imaging char-
acteristics on MR images and dual-phase
spiral CT scans are listed in Table 1.
Regarding the nature of the lesion, the
readers were additionally asked to rate
their confidence level for diagnosing the
presence of a malignant lesion on a five-
point scale (definitely not, probably not,
possibly, probably, definitely). The confi-
dence level of the reader on the imaging
diagnosis was also rated on a five-point
scale. When patients had more than one
type of liver lesion, the clinically most
important lesion was marked by the on-
site radiologists for evaluation by the in-
dependent off-site readers to ensure that
identical lesions were evaluated by using
both imaging modalities.
Forming the Reference Diagnosis
The off-site interpretation of dual-
phase spiral CT scans and Mn-DPDP–en-
hanced MR images was compared with
the reference diagnosis, which was
formed on site by means of interpreta-
tion of all available data in each patient.
These data included all imaging data
(findings of US, CT, MR imaging, and
other imaging if available), clinical data,
laboratory data, as well as data from fol-
low-up examinations. Follow-up dura-
tion was a minimum of 3 months and a
maximum of 1 year. Follow-up examina-
tions were part of the clinical routine and
not part of the study protocol. We at-
tempted to obtain histopathologic con-
firmation for reference diagnoses if le-
sions were not considered benign or if
they were not apparent metastases from a
known primary tumor.
Statistical Analyses
Differences in baseline characteristics
between patients with and those without
histopathologic information were ana-
lyzed by using t tests for continuously
distributed variables and 2 tests for all
other variables. For each imaging modal-
ity, accuracy, sensitivity, and specificity
of each scored item were calculated by
using the reference diagnosis as the ref-
erence standard. The differences between
Mn-DPDP–enhanced MR imaging and
dual-phase spiral CT with regard to these
measures were analyzed by using the Mc-
Nemar test (two-tailed). We analyzed
whether the diagnostic confidence level
for malignancy of a lesion was worse
than, equal to, or better with Mn-DPDP–
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enhanced MR imaging or with dual-
phase spiral CT by using the binomial
test (two-tailed).
Additionally, performance of Mn-
DPDP–enhanced MR imaging and dual-
phase spiral CT in indicating malignancy
of focal liver lesions was compared and
analyzed by using receiver operating
characteristic (ROC) curves (one-tailed).
For all analyses we used an  of 5%. The
ROC analysis was performed with dedi-
cated software (Rockit; Charles E. Metz,
University of Chicago, Ill), and all other
analyses were performed with standard
statistical software (SAS; SAS Institute,
Cary, NC). Since overall results with ei-
ther the consensus off-site readings or
the first off-site readings were identical,
we included only our findings concern-
ing the first readings.
RESULTS
Complete data were acquired for 145 of
152 eligible patients. One patient with-
drew, two had a reference diagnosis of
lesions classified as “other,” which could
not be matched to diagnoses determined
with imaging findings, and with four pa-
tient technical problems with the CT oc-
curred, such that classification of lesions
was impossible. Only one patient experi-
enced an adverse event (thirst) after the
Mn-DPDP administration. No other ad-
verse events related to drugs used in the
trial occurred. Mean age of the 145 partic-
ipants was 58.3 years (61 [42%] women, 84
[58%] men]). A disagreement in classifica-
tion with Mn-DPDP–enhanced MR imag-
ing and dual-phase spiral CT occurred in
43 patients. Although 10 patients were sus-
pected of having focal liver lesions when
they were included in the study, no lesions
could be detected by using either Mn-
DPDP–enhanced MR imaging or dual-
phase spiral CT. Histopathologic informa-
tion was available for deciding on the
reference diagnosis in 77 (57%) of 135 de-
tected lesions. For the other 58 (43%) le-
sions, biopsy was considered unethical be-
cause lesions were considered benign
lesions or metastases from a known pri-
mary tumor.
Sixty-five (84%) of 77 patients with
histopathologic information had malig-
nant lesions versus 32 (47%) of 68 pa-
tients without such information (P 
.001). There was no difference in age or
sex distribution across these groups. De-
tected liver lesions were diagnosed as 70
liver metastases, 21 hepatocellular carci-
nomas (HCCs), 12 hemangiomas, eight
cysts, six instances of focal nodular hy-
perplasia, five adenomas, three regenera-
tive nodules, two scars, two cholangio-
carcinomas, one adenocarcinoma, one
non-Hodgkin lymphoma, one cancer of
the gallbladder, one sarcoma, one calcifi-
cation, and one abscess. Illustrative cases
are shown in Figures 1–4.
Table 2 shows that in the 145 patients,
classification was more often correct with
Mn-DPDP–enhanced MR imaging than
with dual-phase spiral CT (P .001). This
difference remained when analyses were
confined to the 77 patients with histo-
pathologically confirmed diagnoses (P 
.004). When analyzing all 145 patients,
the classification was correct with Mn-
DPDP–enhanced MR imaging but wrong
with dual-phase spiral CT in 34 cases,
whereas in nine cases the classification
was correct with dual-phase spiral CT but
wrong with Mn-DPDP–enhanced MR im-
aging. By confining the analysis to the 77
patients with histopathologically con-
firmed diagnoses, these data were 19 and
five cases, respectively.
Concerning the differentiation be-
tween benign or malignant lesions, Mn-
DPDP–enhanced MR imaging more of-
ten than dual-phase spiral CT evaluation
led to the correct diagnosis (Table 2). This
was found for the analyses in all 145 pa-
tients (P  .001) and for those in the 77
patients with histopathologically con-
firmed diagnoses (P  .001). In the anal-
ysis of all 145 patients, we found that in
33, diagnosis of a lesion as either malig-
nant or benign was correct with Mn-
DPDP–enhanced MR imaging but wrong
with dual-phase spiral CT, while the di-
agnosis was correct with dual-phase spi-
ral CT and wrong with Mn-DPDP–en-
hanced MR imaging in eight. When the
analysis was confined to the patients
with histopathologically confirmed diag-
nosis, these data were 16 and two, respec-
tively.
Sensitivity and specificity for the dif-
ferentiation between malignant and be-
nign lesions with Mn-DPDP–enhanced
MR imaging were better than they were
with dual-phase spiral CT (Table 3) and
remained better when the analyses were
restricted to the patients with histopath-
ologic confirmation. We summarized
and compared the diagnostic perfor-
mance regarding the evaluation of malig-
nancy with both imaging modalities by
constructing ROC curves (Fig 5). Because
the area under the ROC curve for Mn-
DPDP–enhanced MR imaging is larger
than the area under the ROC curve for
dual-phase spiral CT, the diagnostic per-
formance with Mn-DPDP–enhanced MR
imaging for this classification surpasses
that of dual-phase spiral CT (P  .034).
Table 2 shows that the classification as
either hepatocellular or nonhepatocellu-
lar was correct more often with Mn-
DPDP–enhanced MR imaging than with
dual-phase spiral CT. This is true for both
the whole-group analyses (P  .001) and
for the subgroup with histopathologi-
cally confirmed diagnoses (P  .033). In
46 of 145 cases, diagnosis of a lesion as
either hepatocellular or nonhepatocellu-
lar was correct with Mn-DPDP–enhanced
MR imaging but wrong with dual-phase
spiral CT, whereas in nine, the diagnosis
was correct with dual-phase spiral CT and
wrong with Mn-DPDP–enhanced MR im-
aging. Confining the analysis to the his-
topathologically confirmed diagnoses,
these data were 16 and six, respectively.
In terms of sensitivity and specificity,
Mn-DPDP–enhanced MR imaging per-
formed better than dual-phase spiral CT
in the whole group as well as in the group
with histopathologic confirmation (Ta-
ble 3).
Incorrect diagnoses with dual-phase
spiral CT occurred in a wide disease spec-
trum ranging from metastasis, HCC, and
cholangiocarcinoma to hemangioma and
focal nodular hyperplasia. Incorrect diag-
noses determined exclusively with Mn-
DPDP–enhanced MR imaging were al-
most all metastases, particularly those
originating from primary colorectal car-
cinoma. In these patients, the Mn-DPDP–
enhanced MR images demonstrated some
hyperintense ring- or rim-like zones at the
periphery of the tumor, with varying de-
grees of enhancement (Fig 4).
Lesions were correctly classified as ma-
lignant by using Mn-DPDP–enhanced
MR imaging as well as by using dual-
phase spiral CT in 55 of 97 patients. In
the 55 lesions, radiologists were more
confident diagnosing malignancy with
Mn-DPDP–enhanced MR imaging than
with dual-phase spiral CT in 34 (62%)
patients, equally confident in 17 (31%),
and less confident in four (7%). Taking
into account all correct diagnoses, inter-
preters of Mn-DPDP–enhanced MR im-
ages were extremely confident of their
diagnosis at review of 55 (51%) of 108
MR images versus five (6%) of 83 dual-
phase spiral CT images.
DISCUSSION
Results from this multicenter trial, in
which state-of-the-art liver imaging tech-
niques for characterizing focal liver le-
sions were compared, indicate that Mn-
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DPDP–enhanced MR imaging performs
favorably compared with contrast-en-
hanced dual-phase spiral CT. These fa-
vorable results for Mn-DPDP–enhanced
MR imaging were found for differentiat-
ing benign from malignant lesions and
for characterizing lesions as either hepa-
tocellular or nonhepatocellular. The com-
parison of ROC curves indicates that the
classification of a lesion as either benign
or malignant would be correct more of-
ten with Mn-DPDP–enhanced MR imag-
ing than with dual-phase spiral CT (24).
Also, radiologists were more confident of
their interpretation of Mn-DPDP–en-
hanced MR images than of dual-phase
spiral CT scans.
We should, however, discuss some
benefits and limitations of the study be-
fore turning to the clinical consequences
of our findings. First, the use of the same
state-of-the-art equipment in all six cen-
ters for dual-phase spiral CT and for Mn-
DPDP–enhanced MR imaging ensured
that data could be pooled and compared.
Comparison between modalities was also
aided by the interpretation of lesions by
the independent radiologists experi-
enced in these techniques. Although not
all images were read in duplo, when clas-
sifications of images differed between in-
terpreters, a double reading and, when
necessary, a consensus interpretation
were performed. Overall results of the
comparison between dual-phase spiral
CT and Mn-DPDP–enhanced MR imag-
ing after these further readings were not
different from those of the first readings,
and this resulted in a strengthening of
the validity of the findings. We reported
results of the first readings, as this situa-
tion best reflects clinical routine.
Second, the reference standard we used
was based on all available imaging data
combined with all available clinical data.
Ethical considerations necessitated that
we refrained from obtaining histopatho-
logic data (which involves performing an
invasive diagnostic procedure that carries
a certain risk to the patient) when, on the
basis of all available information, a lesion
was considered benign or could already
be diagnosed with great certainty. Al-
though the lack of histopathologic con-
firmation could have led to misdiagnosis,
we consider this undifferential because
we found that discrepancies in diagnosis
between Mn-DPDP–enhanced MR imag-
ing and dual-phase spiral CT occurred as
often in patients in whom diagnoses
were histopathologically confirmed as
they occurred in those in whom this con-
firmation was lacking. If anything, this
misclassification would therefore have
led to an underestimation of the differ-
ences between both imaging modalities.
Additionally, including only patients
with histopathologically proved diag-
noses yielded the same results as includ-
ing all patients for classifying the nature
(malignant vs benign) and type of liver
Figure 1. Images show colorectal carcinoma in a 62-year-old woman who was evaluated for staging of the disease. Retrospectively,
transverse spiral CT scans obtained in the (a) arterial and (b) portal phases showed a poorly defined region in the left hepatic lobe,
with slight enhancement in the arterial phase, which was not visualized in the portal phase. Readers of the CT scans did not identify
the lesion. On the transverse (c) Mn-DPDP–enhanced T2-weighted (3,200/138; flip angle, 180°) and (d) Mn-DPDP–enhanced
T1-weighted (170/4.4; flip angle, 80°) MR images, the lesion was clearly visualized (arrow), and readers of the Mn-DPDP–enhanced
MR images classified the lesion as metastatic disease. The final histopathologic diagnosis was liver metastasis from colon carcinoma.
Figure 2. Transverse images show HCC in a 51-year-old man. Images were arranged to depict
the same lesion at the same level in the anterior segment of the right hepatic lobe. Transverse
dual-phase spiral CT scans show that the lesion is inhomogeneously enhanced on the image
obtained during the (a) arterial phase and predominantly hypoattenuating on the image ob-
tained during the (b) portal venous phase. Despite these features, readers of the dual-phase spiral
CT scans classified this as a benign lesion. (c) T1-weighted (170/4.4; flip angle, 80°) Mn-DPDP–
enhanced MR image shows marked, slightly inhomogeneous enhancement. The conspicuity of
the lesion (white arrow) greatly improved because of the presence of an unenhanced hypointense
rim (tumor capsule) marking the border of the lesion. Readers of the Mn-DPDP–enhanced MR
images classified this lesion as HCC, which was histopathologically confirmed.
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lesions (hepatocellular vs nonhepatocel-
lular).
Third, the latest Mn-DPDP–enhanced
MR images were obtained approximately
1 hour after contrast material administra-
tion, and the latest dual-phase spiral CT
images were obtained approximately 8
minutes after contrast material administra-
tion. Although obtaining 24-hour postcon-
trast Mn-DPDP–enhanced MR images
would probably help to improve the char-
acterization of certain liver lesions, as in
some subtypes of HCC and colorectal liver
metastasis, excretion of Mn-DPDP is im-
paired and the retention of Mn-DPDP per-
sists, giving a characteristic late enhance-
ment on Mn-DPDP–enhanced MR images.
Also, the central scar of focal nodular hy-
perplasia and the pseudocapsule of HCC
would become more conspicuous on 24-
hour postcontrast Mn-DPDP–enhanced
MR images than on 1-hour postcontrast
images (25). On the other hand, obtaining
postcontrast dual-phase spiral CT images at
a later time would not have aided in the
characterization of focal liver lesions. This
is because the CT contrast agent has such a
low affinity for liver tissue and is cleared so
swiftly from the system that there would
be no difference with 8-minute postcon-
trast images.
Although of no influence on the re-
sults, enhancement patterns of focal liver
lesions on both Mn-DPDP–enhanced MR
images and dual-phase spiral CT scans
were not specifically recorded per patient.
Therefore, the correlation between the en-
hancement pattern and the grade of HCC
tumor differentiation could not be ad-
dressed. Previous studies have indicated
that in patients with HCC the degree of
Mn-DPDP uptake was closely related to the
grade of tumor differentiation (11,15). This
enhancement pattern can vary from gen-
erally homogeneous enhancement in well-
differentiated HCC to irregular patchy or
nodular enhancement or even entirely het-
erogeneous appearances in poorly differen-
tiated lesions. Similar findings were also
observed in contrast-enhanced CT studies
of HCC (17,18,20).
Dual-phase spiral CT was associated
with incorrect diagnoses concerning the
type and the nature of focal liver lesions
in a much wider disease spectrum than
was Mn-DPDP–enhanced MR imaging.
This variability in lesion characterization
reflects that the appearance of liver le-
sions on dual-phase spiral CT scans is
influenced by many physiologic, patho-
logic, and technical factors, besides le-
sion attributes (eg, neovascularity, grade
of differentiation). This might have led to
the erroneous classification of a lesion as
shown in Figure 2 that was classified as
benign, despite the fact that it lacked be-
nign features, and to the classification of
the lesion in Figure 3 that was interpreted
as a calcification. At dual-phase spiral CT,
atypical enhancement patterns of focal
liver lesions are not uncommon, which
complicates lesion characterization. In
our study, this was reflected by the read-
ers being less confident in characterizing
a lesion as benign or malignant with
dual-phase spiral CT than they were with
Mn-DPDP–enhanced MR imaging, even
when both classifications were correct.
Atypical Mn-DPDP–enhanced MR pat-
terns are less common, and in our study,
they mainly occurred in cases errone-
ously classified as HCC instead of as
metastasis (Fig 4). However, because the
rim-like enhancement on Mn-DPDP–
enhanced MR images, as often seen in
HCC, is theoretically unlikely to appear
in metastases of the colon, we believe
that some mistake might have been
Figure 3. Transverse images show liver metastases in a 56-year-old man. The suboptimal
dual-phase spiral CT scans obtained in the (a) hepatic arterial phase and (b) portal venous phase
show no focal lesions apart from a slightly hyperattenuating area (arrow in a) in the upper right
hepatic lobe visible in a that was not classified as metastasis but as possible calcification. (c) On
the T1-weighted (170/4.4; flip angle, 80°) Mn-DPDP–enhanced MR image, lesions can be seen
with better contrast and conspicuity as hypointense lesions visible in the upper right hepatic
lobe. Both posterior lesions were classified as metastasis (open and solid white arrows), and the
anterior lesion (black arrow) was classified as benign. The histopathologic diagnosis of the
posterior lesions was liver metastasis from adenocarcinoma of an unknown primary tumor.
Figure 4. Transverse images show multiple focal liver lesions in a 61-year-old man. Only the
lesion located in the left hepatic lobe (arrow) was selected for evaluation. (a) Dual-phase spiral CT
revealed a nonenhanced low-attenuating lesion on the image obtained in the arterial phase.
(b) Scan obtained in the portal venous phase depicts faint peripheral zone enhancement. On the
basis of findings of dual-phase spiral CT, metastasis was the diagnosis. (c) On the T1-weighted
(170/4.4; flip angle, 80°) Mn-DPDP–enhanced MR image, the lesion demonstrates marked en-
hancement in the peripheral zone. Such rim-like enhancement was generally irregular in thick-
ness and at some parts was nodular in shape. The central bulk of the lesion showed no obvious
enhancement. On the basis of findings of Mn-DPDP–enhanced MR, the diagnosis was a malig-
nant lesion of hepatocellular origin, possibly HCC. The histopathologic diagnosis was liver
metastasis from primary colon carcinoma.
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made regarding the sampling or histo-
pathologic diagnosis. The underlying
mechanism for the occurrence of rim-like
enhancement in some metastatic liver
tumors has been attributed to several
causes (26). First, peritumoral malignant
infiltration into neighboring normal liver
parenchyma can result in intermingling of
nonhepatocellular malignant cells with
normal functioning hepatocytes in the pe-
ripheral region of liver metastasis. Second,
compression of surrounding normal liver
tissue by a metastatic tumor mass may lead
to impaired Mn-DPDP excretion or persis-
tent Mn-DPDP retention because of the
compressed bile canaliculi in these areas
(26).
Kane et al (23) also reported such a
rim-like enhancement phenomenon in a
patient with cholangiocarcinoma, which
is known to infiltrate neighboring nor-
mal liver tissue. Thus, although Mu-
rakami et al (11) stated that the periph-
eral enhancement phenomenon of
metastases is unlikely to cause diagnostic
confusion with HCC, we found this rim
enhancement of some metastatic lesions
so intense that a clear differentiation
from poorly differentiated HCC, which is
known to take up Mn-DPDP to a much
lesser degree than typically well-differen-
tiated HCC (15,22), could not be deter-
mined.
Despite our findings that Mn-DPDP–
enhanced MR imaging is superior to dual-
phase spiral CT for characterizing focal
liver lesions, there are problems in imple-
menting this outcome in patient care.
Because of shortages in the times that MR
imaging examinations can be scheduled
(MR imaging is more time consuming
and fewer machines are available) and
cost issues, dual-phase spiral CT might
remain the first-choice imaging modality
for the majority of patients suspected of
having pathologic focal liver lesions. In
this case, Mn-DPDP–enhanced MR imag-
ing could be reserved as a second-stage
diagnostic tool (before turning to inva-
sive procedures) when the diagnosis
would still be inconclusive by using dual-
phase spiral CT or other imaging findings
combined with clinical information. Per-
haps increasing the MR imager availabil-
ity together with lowering prices for MR
contrast agents may boost the role of MR
imaging in examination of the liver.
Since the time of this study, other liver-
specific MR contrast agents (reticuloen-
dothelial or hepatobiliary), such as ga-
doxetic acid disodium (Eovist; Schering,
Berlin, Germany) and gadobenate dime-
glumine (Multihance; Bracco, Milan, Italy),
have been proposed and have potential
for characterizing liver lesions (27–29).
Although promising, for now these
agents have not been approved by the
Food and Drug Administration, and since
no findings of comparative studies of
these agents have been published, their
role is not yet certain. Also, new dynamic
gadolinium-enhanced MR techniques for
the classification of focal liver lesions
show promising results. Because the per-
formance of Mn-DPDP–enhanced MR
imaging has not yet been compared with
that of the newly developed dynamic ga-
dolinium-enhanced MR imaging, it is not
clear which technique is preferred, al-
though both seem to surpass the perfor-
mance of dual-phase spiral CT (30).
In conclusion, results from this multi-
center study show that Mn-DPDP–en-
TABLE 2
Correctly Classified Diagnoses in 145 Patients and in 77 Patients with
Histologically Confirmed Diagnoses
Correct Diagnoses
No. of Patients with Correct
Diagnoses at Dual-Phase
Spiral CT
No. of Patients with Correct
Diagnoses at Mn-DPDP–
enhanced MR Imaging P Value
Overall 83 (57) 108 (74) .001
43 (56)* 57 (74)* .004*
Differentiation between
Malignant vs benign 98 (68) 123 (85) .001
53 (69)* 67 (87)* .001*
Hepatocellular vs 93 (64) 130 (90) .001
nonhepatocellular 57 (74)* 67 (87)* .033*
Note.—Number in parentheses is the percentage.
* Data in 77 patients with histopathologically confirmed diagnoses.
TABLE 3
Sensitivity and Specificity in 145 Patients and in 77 Patients with Histologically
Confirmed Diagnoses
Differentiation of Lesions and Data
Dual-Phase
Spiral CT*
Mn-DPDP–enhanced
MR Imaging* P Value
Malignant vs benign
Sensitivity
71 (69/97) 90 (87/97) .001†
72 (47/65)† 91 (59/65)† .002
Specificity
60 (29/48) 75 (36/48) .17
50 (6/12)† 67 (8/12)† .63†
Hepatocellular vs nonhepatocellular
Sensitivity
56 (20/36) 89 (32/36) .008
61 (14/23)† 91 (21/23)† .07†
Specificity
67 (73/109) 90 (98/109) .001
80 (43/54)† 85 (46/54)† .50†
* Data are percentages. Data in parentheses are the number of diagnoses correctly identified by
using the modality/total number correct.
† Data in 77 patients with histopathologically confirmed diagnoses.
Figure 5. ROC comparative analysis of Mn-
DPDP–enhanced MR imaging (EMR) and dual-
phase spiral CT (DP-SCT) regarding the pres-
ence of a malignant lesion indicates better
performance of Mn-DPDP–enhanced MR im-
aging compared with that of dual-phase spiral
CT (difference between Mn-DPDP–enhanced
MR and dual-phase spiral CT in the under-
curve area  0.07; P  .03).
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hanced MR imaging is safe and well
tolerated and that it is superior to con-
trast-enhanced dual-phase spiral CT for
distinguishing malignant from benign
and hepatocellular from nonhepatocel-
lular focal liver lesions.
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